KPMG Releases Positive Report on Psychedelics

Psychedelic medicine’s acceptance by institutional investors is one of the major factors deciding the sector’s future. Without Wall Street getting on board, stock prices will be under constant pressure and capital will be hard to come by, thus affecting the odds of making it through the costly clinical trial process.

Which is why the news of KPMG putting out a report on psychedelics was low-key big news. KPMG is a major multinational professional services network and one of the “Big Four” accounting organizations, so a positive report on the industry, even a relatively small one, can go a long way in legitimizing the space in the eyes of more conservative institutional investors.

A link to the full report can be found here

.